 Umeclidinium bromide(TOP), vilanterol(BOTTOM) | |
| Combination of | |
|---|---|
| Umeclidinium bromide | Muscarinic antagonist |
| Vilanterol | Ultra-long-acting β2 agonist |
| Clinical data | |
| Trade names | Anoro Ellipta, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Umeclidinium bromide/vilanterol, sold under the brand nameAnoro Ellipta, among others, is afixed-dose combination medication for the treatment ofchronic obstructive pulmonary disease (COPD).[5][6] It is administered by inhalation.
The most common side effects includeupper respiratory tract infections,urinary tract infections,pharyngitis,sinusitis,nasopharyngitis, headache, cough,oropharyngeal pain, constipation and dry mouth.[4]
In 2022, it was the 211th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
